Despite advancements in care, prostate cancer is one of the most frequently diagnosed cancers around the world. This Movember, we’re focused on raising awareness of prostate cancer.
Nov 04, 2021

Raising awareness of prostate cancer community needs

This Movember, a month dedicated to raising awareness of men’s health issues, we're focused on awareness of prostate cancer—a leading cause of cancer deaths among males.1

Prostate cancer around the world

Despite advancements in care, prostate cancer is the most frequently diagnosed cancer in over 50% of countries (112/185), with more 1.4 million new cases and 375 000 deaths in 2020 alone.2,3

Bringing innovation to this underserved population has the potential to transform how advanced prostate cancer is treated.

Our commitment

At Novartis, we are driving forward new research for males living with advanced prostate cancer. Hear from Dr. Susanne Schaffert, President of Novartis Oncology; Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development; and Dr Andrew Cavey, Global Program Head, Prostate Cancer for Advanced Accelerator Applications (AAA), a Novartis Company, on the need for continued discussions about men’s health and Novartis’ commitment to the prostate cancer community.

Reimagining outcomes for males

Movember RLT

We’re committed to advancing care for males with prostate cancer through new research aimed at delivering hope. We’re developing an emerging form of nuclear medicine called targeted radioligand therapy. This exciting precision medicine may have potential in the treatment of advanced prostate cancer.

Learn more about the potential of radioligand therapy


  1. World Health Organization. Global Cancer Observatory. Cancer Today. Accessed October 1, 2021.
  2. Ferlay J, Siegel RL, Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):225-227. doi:10.3322/caac.21660.
  3. Bott S, NG K, Giona S. The epidemiology of prostate cancer. In: Prostate Cancer. 2021:1. doi:10.36255/exonpublications.prostatecancer.epidemiology.2021.